Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma.
Kinget L, Roussel E, Lambrechts D, Boeckx B, Vanginderhuysen L, Albersen M, Rodríguez-Antona C, Graña-Castro O, Inglada-Pérez L, Verbiest A, Zucman-Rossi J, Couchy G, Caruso S, Laenen A, Baldewijns M, Beuselinck B. Kinget L, et al. Among authors: laenen a. Cancers (Basel). 2021 Mar 28;13(7):1554. doi: 10.3390/cancers13071554. Cancers (Basel). 2021. PMID: 33800656 Free PMC article.
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
Jongen L, Floris G, Boeckx B, Smeets D, Lambrechts D, Vander Borght S, Laenen A, Mann G, Cutler RE Jr, Lalani AS, Neven P, Wildiers H. Jongen L, et al. Among authors: laenen a. Breast Cancer Res Treat. 2019 Feb;174(1):55-63. doi: 10.1007/s10549-018-5049-7. Epub 2018 Nov 19. Breast Cancer Res Treat. 2019. PMID: 30456437
Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E, Busschaert P, Laenen A, Moerman P, Han SN, Neven P, Lambrechts D, Vergote I. Van Nieuwenhuysen E, et al. Among authors: laenen a. Neoplasia. 2019 Jun;21(6):582-590. doi: 10.1016/j.neo.2019.03.014. Epub 2019 May 1. Neoplasia. 2019. PMID: 31054497 Free PMC article.
Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.
Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B. Verbiest A, et al. Among authors: laenen a. Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. Epub 2019 May 25. Clin Genitourin Cancer. 2019. PMID: 31229459
Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Beuselinck B, Pans S, Bielen J, De Wever L, Noppe N, Vanderschueren G, De Keyzer F, Baldewijns M, Lerut E, Laenen A, Verbiest A, Roussel E, Albersen M, Vandecaveye V. Beuselinck B, et al. Among authors: laenen a. Acta Oncol. 2020 Jul;59(7):818-824. doi: 10.1080/0284186X.2020.1750696. Epub 2020 Apr 16. Acta Oncol. 2020. PMID: 32297532
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors.
Haaker L, Tryssesoone L, Renders I, Verbiest A, Lerut E, Baldewijns M, Bourgain C, Roussel E, Van den Bulck H, Wynendaele W, Laguerre B, Rioux-Leclercq N, Oudard S, Laenen A, Debruyne PR, Albersen M, Beuselinck B. Haaker L, et al. Among authors: laenen a. Urol Oncol. 2020 Aug;38(8):686.e1-686.e9. doi: 10.1016/j.urolonc.2020.04.031. Epub 2020 May 17. Urol Oncol. 2020. PMID: 32430250
MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets.
Verbiest A, Van Hoef V, Rodriguez-Antona C, García-Donas J, Graña-Castro O, Albersen M, Baldewijns M, Laenen A, Roussel E, Schöffski P, Wozniak A, Caruso S, Couchy G, Zucman-Rossi J, Beuselinck B. Verbiest A, et al. Among authors: laenen a. PLoS One. 2020 Sep 11;15(9):e0238809. doi: 10.1371/journal.pone.0238809. eCollection 2020. PLoS One. 2020. PMID: 32915890 Free PMC article.
Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort.
Thijssen S, Wildiers H, Punie K, Beuselinck B, Clement P, Remmerie C, Berteloot P, Han S, Van Nieuwenhuysen E, Van Gorp T, Vergote I, Smeets A, Nevelsteen I, Floris G, Weltens C, Menten J, Janssen H, Laenen A, Neven P. Thijssen S, et al. Among authors: laenen a. J Cancer Res Clin Oncol. 2021 Apr;147(4):1041-1048. doi: 10.1007/s00432-020-03487-1. Epub 2021 Jan 20. J Cancer Res Clin Oncol. 2021. PMID: 33471187 Clinical Trial.
MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma.
Kinget L, Roussel E, Verbiest A, Albersen M, Rodríguez-Antona C, Graña-Castro O, Inglada-Pérez L, Zucman-Rossi J, Couchy G, Job S, de Reyniès A, Laenen A, Baldewijns M, Beuselinck B. Kinget L, et al. Among authors: laenen a. Cancers (Basel). 2021 Jun 21;13(12):3099. doi: 10.3390/cancers13123099. Cancers (Basel). 2021. PMID: 34205829 Free PMC article.
Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study.
Demasure S, Spriet I, Debruyne PR, Laenen A, Wynendaele W, Baldewijns M, Dumez H, Clement PM, Wildiers H, Schöffski P, Roussel E, Kinget L, Albersen M, Beuselinck B. Demasure S, et al. Among authors: laenen a. Acta Oncol. 2022 Jan;61(1):22-29. doi: 10.1080/0284186X.2021.1989720. Epub 2021 Oct 28. Acta Oncol. 2022. PMID: 34711121
254 results